NCT04339023View on ClinicalTrials.gov

Open-Label Placebo Treatment for Acute Postoperative Pain

NACompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

May 12, 2020

Primary Completion Date

January 31, 2023

Study Completion Date

January 31, 2023

Conditions
Postoperative Pain
Interventions
DRUG

Open-Label Placebo

in addition to Treatment as usual, patients receive placebos without concealment (open-label placebo, OLP)

OTHER

treatment as usual

usual medication intake following minimally invasive TLIF. TAU consists of 3 gram Paracetamol per os a day, a patient-controlled morphine pump (Maximum of 2 milligram (mg) every 12 minutes) and rescue medication (1000 mg of Metamizol, maximum every 6 hours)

Trial Locations (1)

4031

University Hospital of Basel, Department of Anesthesia, Basel

All Listed Sponsors
lead

University Hospital, Basel, Switzerland

OTHER

NCT04339023 - Open-Label Placebo Treatment for Acute Postoperative Pain | Biotech Hunter | Biotech Hunter